Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 11, 2013 - Issue 8
Submit an article Journal homepage
869
Views
25
CrossRef citations to date
0
Altmetric
Special Report

Streptococcus pneumoniae infection: a Canadian perspective

Xianding Deng Department of Laboratory Medicine & Pathobiology, University of Toronto Public Health Ontario, 81 Resources Road, M9P 3T1, Toronto, ON, Canada. [email protected]; Department of Microbiology, Mount Sinai Hospital, Toronto, ON, Canada; Department of Laboratory Medicine & Pathobiology, University of Toronto Public Health Ontario, 81 Resources Road, M9P 3T1, Toronto, ON, Canada. [email protected]; Department of Microbiology, Mount Sinai Hospital, Toronto, ON, Canada
,
Deirdre Church Department of Pathology and Laboratory Medicine, University of Calgary, 9-3535 Research Road NW, Calgary, AB, T2L 2K8, Canada; Calgary Laboratory Services, Calgary, AB, Canada; Department of Pathology and Laboratory Medicine, University of Calgary, 9-3535 Research Road NW, Calgary, AB, T2L 2K8, Canada; Calgary Laboratory Services, Calgary, AB, Canada
,
Otto G Vanderkooi Department of Pathology and Laboratory Medicine, University of Calgary, 9-3535 Research Road NW, Calgary, AB, T2L 2K8, Canada; Calgary Laboratory Services, Calgary, AB, Canada; Department of Microbiology, Immunology, and Infectious Diseases, University of Calgary, AB, Canada; Department of Pediatrics, Section of Pediatric Infectious Diseases, Alberta Children’s Hospital, Calgary, AB, Canada
,
Donald E Low Department of Laboratory Medicine & Pathobiology, University of Toronto Public Health Ontario, 81 Resources Road, M9P 3T1, Toronto, ON, Canada; Department of Microbiology, Mount Sinai Hospital, Toronto, ON, Canada; Department of Laboratory Medicine & Pathobiology, University of Toronto Public Health Ontario, 81 Resources Road, M9P 3T1, Toronto, ON, Canada; Department of Microbiology, Mount Sinai Hospital, Toronto, ON, Canada
&
Dylan R Pillai Department of Pathology and Laboratory Medicine, University of Calgary, 9-3535 Research Road NW, Calgary, AB, T2L 2K8, Canada; Calgary Laboratory Services, Calgary, AB, Canada; Department of Microbiology, Immunology, and Infectious Diseases, University of Calgary, AB, Canada
Pages 781-791 | Published online: 10 Jan 2014

References

  • Ausina V, Coll P, Sambeat M et al. Prospective study on the etiology of community-acquired pneumonia in children and adults in Spain. Eur. J. Clin. Microbiol. Infect. Dis. 7(3), 342–347 (1988).
  • Arditi M, Mason EO Jr, Bradley JS et al. Three-year multicenter surveillance of pneumococcal meningitis in children: clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use. Pediatrics 102(5), 1087–1097 (1998).
  • Bluestone CS, Martin L. Ten-year review of otitis media pathogens. Pediatr. Infect. Dis. J. 11(Suppl.), 7–11 (1992).
  • O'Brien KL, Millar EV, Zell ER, Bronsdon M et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J. Infect. Dis. 196(8), 1211–1220 (2007).
  • De Wals P, Robin E, Fortin E et al. Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr. Infect. Dis. J. 27(11), 963–968 (2008).
  • Wals PD, Carbon M, Sévin E et al. Reduced physician claims for otitis media after implementation of pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr. Infect. Dis. J. 28(9), 271–275 (2009).
  • Grijalva CG, Nuorti JP, Arbogast PG et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369(9568), 1179–1186 (2007).
  • Poehling KA, Szilagyi PG, Grijalva CG et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics 119, 707–715 (2007).
  • Scheifele D, Halperin S, Pelletier L. Invasive pneumococcal infections in Canadian children, 1991–1998: implications for new vaccination strategies. Clin. Infect. Dis. 31, 58–64 (2000).
  • Robinson KA, Baughman W, Rothrock G et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995–1998: opportunities for prevention in the conjugate vaccine era. JAMA 285(13), 1729–1735 (2001).
  • Kellner JD, Vanderkooi OG, MacDonald J et al. Changing epidemiology of invasive pneumococcal disease in Canada, 1998–2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin. Infect. Dis. 49(2), 205–212 (2009).
  • Munoz-Almagro C, Jordan I, Gene A et al. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin. Infect. Dis. 46, 174–182 (2008).
  • Pai R, Moore MR, Pilishvili T et al. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J. Infect. Dis. 192(11), 1988–1995 (2005).
  • Bettinger JA, Scheifele DW, Kellner JD, Halperin SA et al. The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000–2007. Vaccine 28, 2130–2136 (2010).
  • Isaacman DJ, Mcintosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int. J. Infect. Dis. 14(3), 197–209 (2010).
  • Brueggeman A, Pai R, Crook DW, Beall B. Vaccine escape recombination emerge after pneumococcal vaccination in the United States. PLos Pathog. 3, 1628–1636 (2007).
  • Desai S, McGeer A, Quach Thanh C, Elliott D. Update on the use of conjugate pneumococcal vaccines in childhood. Can. Commun. Dis. Rep. 36(ACS-12), 1–21 (2010).
  • Bernatoniene J, Finn A. Advances in pneumococcal vaccines: advantages for infants and children. Drugs 65(2), 229–255 (2005).
  • Bogaert D, Hermans PW, Adrian PV, Rümke HC, de Groot R. Pneumococcal vaccines: an update on current strategies. Vaccine 22(17), 2209–2220 (2004).
  • Rodgers GL, Klugman KP. The future of pneumococcal disease prevention. Vaccine 29(Suppl. 3), 43–48 (2011).
  • Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J. Clin. Microbiol. 33, 2759–2762 (1995).
  • Feikin DR, Klugman KP. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin. Infect. Dis. 35(5), 547–555 (2002).
  • Hodges RG, Macleod CM. Epidemic pneumococcal pneumonia. V. Final considerations of the factors underlying the epidemic. Am. J. Hyg. 44, 237–243 (1946).
  • Smillie W, Warnock G, White H. Study of a type I pneumococcus epidemic at the State Hospital at Worcester, Massachusetts. Am. J. Public Health 28, 293–298 (1938).
  • Dixon JMS, Lipinski AE. Pneumococcal serotypes causing bacteremia and meningitis: relevance to composition of pneumococcal vaccine. Can. Med. Assoc. J. 125, 263–267 (1981).
  • Lamothe F, Delage G, Laverditre M, Saint-Antoine P. Serogroups and serotypes of pneumococci in Montreal: correlates with age, outcome and indications for vaccinations. Can. Med. Assoc. J. 130, 737–740 (1984).
  • Jette LP, Lamothe F. Surveillance of invasive Streptococcus pneumonia infection in Quebec, Canada from 1984 to 1986: serotype distribution, antimicrobial susceptibility and clinical characteristics. J. Clin. Microbiol. 27(1), 1–5 (1989).
  • Klugman KP. Pneumococcal resistance to antibiotics. Clin. Microbiol. Rev. 3, 171–196 (1990).
  • Joffe MD, Alpern ER. Occult pneumococcal bacteremia: a review. Pediatr. Emer. Care 26, 48–457 (2010).
  • Bettinger JA, Scheifele DW, Halperin SA et al. Invasive pneumococcal infections in Canadian children, 1998–2003: implications for new vaccination programs. Can. J. Public Health 98, 111–115 (2007).
  • Tyrrell GJ, Lovgren M, Chui N et al. Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae pre- and post-seven valent pneumococcal conjugate vaccine introduction in Alberta, Canada, 2000–2006. Vaccine 27, 3553–3560 (2009).
  • Winters M, Patrick DM, Marra F, Buxton J. Epidemiology of invasive pneumococcal disease in BC during the introduction of conjugated pneumococcal vaccine. Can. J. Public Health 99(1), 57–61 (2008).
  • Demczuk WHB, Martin I, Griffith A et al. Serotype distribution of invasive Streptococcus pneumoniae in Canada during the introduction of the 13-valent pneumococcal conjugate vaccine, 2010. Can. J. Microbiol. 58(8), 1008–1017 (2012).
  • Deceuninck G, De Wals P, Boulianne N, De Serres G. Effectiveness of pneumococcal conjugate vaccine using a 2+1 infant schedule in Quebec, Canada. Pediatr. Infect. Dis. J. 29(6), 546–549 (2010).
  • Sahni V, Naus M, Hoang L et al. The epidemiology of IPD in British Columbia following implementation of an infant immunization program: increases in herd immunity and replacement disease. Can. J. Public Health 103(1), 29–33 (2012).
  • Degani N, Navarro C, Deeks SL, Lovgren M. Invasive bacterial diseases in Northern Canada. Emerg. Infect. Dis. 14(1), 34–40 (2008).
  • Plevneshi A, Svoboda T, Armstrong I et al. Population-based surveillance for invasive pneumococcal disease in homeless adults in Toronto. PLoS One 4(9), e7255 (2009).
  • Hennessy TW, Singleton RJ, Bulkow LR et al. Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: progress towards elimination of a health disparity. Vaccine 23, 5464–5473 (2005).
  • Hsu K, Pelton S, Karumuri S et al. Massachusetts Department of Public Health Epidemiologists. Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine. Pediatr. Infect. Dis. J. 24, 17–23 (2005).
  • Hicks LA, Harrison LH, Flannery B et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J. Infect. Dis. 196, 1346–1354 (2007).
  • Williams BG. Estimates of worldwide distribution of child deaths from acute respiratory tract infections. Lancet Infect. Dis. 2, 25–32 (2002).
  • Obaro SK, Madhi SA. Bacterial pneumonia vaccines and childhood pneumonia: are we winning, refining, or redefining? Lancet Infect. Dis. 6, 150–161 (2006).
  • Simonsen L, Taylor RJ, Young-Xu Y, Haber M, May L, Klugman KP. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio. 2(1), e00309–10 (2011).
  • Dubé E, De Wals P, Gilca V et al. Burden of acute otitis media on Canadian families. Can. Fam. Physician 57, 60–65 (2011).
  • Morrow A, De Wals P, Petit G, Guay M, Erickson LJ. The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine. Can. J. Infect. Dis. Med. Microbiol. 18(2), 121–127 (2007).
  • Bluestone CD, Stephenson JS, Martin LM. Ten-year review of otitis media pathogens. Pediatr. Infect. Dis. J. 11(Suppl. 8), S7–S11 (1992).
  • Black S, Shinefield H, Fireman B et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J. 19, 187–195 (2000).
  • Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr. Infect. Dis. J. 22, 10–16 (2003).
  • Brunton S, Pichichero ME. Acute otitis media: influence of the PCV-7 vaccine on changes in the disease and its management. J. Fam. Practice 54, 11–16 (2005).
  • Vayalumkal J, Kellner JD. Tympanocentesis for the management of acute otitis media in children: a survey of Canadian pediatricians and family physicians. Arch. Pediatr. Adolesc. Med. 158(10), 962–965 (2004).
  • De Wals P, Lefebvre B, Defay F, Deceuninck G, Boulianne N. Invasive pneumococcal diseases in birth cohorts vaccinated with PCV-7 and/or PHiD-CV in the province of Quebec, Canada. Vaccine 30, 6416–6420 (2012).
  • Earnshaw SR, McDade CL et al. Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada. BMC Infect. Dis. 12, 101 (2012).
  • Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 29(49), 9127–9131 (2011).
  • Kaplan SL, Barson WJ, Lin PL et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 32(3), 203–207 (2013).
  • Hortal M, Estevan M, Laurani H, Iraola I, Meny M, Paysandú/Salto Study Group. Hospitalized children with pneumonia in Uruguay: pre and post introduction of 7 and 13-valent pneumococcal conjugated vaccines into the National Immunization Program. Vaccine 30(33), 4934–4938 (2012).
  • Cohen R, Levy C, Bingen E et al. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr. Infect. Dis. J. 31(3), 297–301 (2012).
  • Kellner JD, Scheifele D, Vanderkooi OG et al. Effects of routine infant vaccination with the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization with Streptococcus pneumoniae in children in Calgary, Canada. Pediatr. Infect. Dis. J. 27(6), 526–532 (2008).
  • O'Brien KL, Millar EV, Zell ER Bronsdon M et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J. Infect. Dis. 196(8), 1211–1220 (2007).
  • Revai K, McCormick DP, Patel J, Grady JJ, Saeed K, Chonmaitree T. Effect of pneumococcal conjugate vaccine on nasopharyngeal bacterial colonization during acute otitis media. Pediatrics 117(5), 1823–1829 (2006).
  • Huang SS, Platt R, Rifas-Shiman SL, Pelton SI, Goldmann D, Finkelstein JA. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 116(3), 408–413 (2005).
  • Chien YW, Vidal JE, Grijalva CG Bozio C et al. Density interactions between Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus in the nasopharynx of young Peruvian children. Pediatr. Infect. Dis. J. 32(1), 72–77 (2013).
  • Kwambana BA, Barer MR, Bottomley C, Adegbola RA, Antonio M. Early acquisition and high nasopharyngeal co-colonisation by Streptococcus pneumoniae and three respiratory pathogens amongst Gambian new-borns and infants. BMC Infect. Dis. 11, 175 (2011).
  • Spijkerman J, Prevaes SM, van Gils EJ et al. Long-term effects of pneumococcal conjugate vaccine on nasopharyngeal carriage of S. pneumoniae, S. aureus, H. influenzae and M. catarrhalis. PloS One. 7(6), e39370 (2012).
  • Madhi SA, Adrian P, Kuwanda L, Cutland C, Albrich WC, Klugman KP. Long-term effect of pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae – and associated interactions with Staphylococcus aureus and Haemophilus influenzae colonization – in HIV-infected and HIV-uninfected children. J. Infect. Dis. 196, 1662–1666 (2007).
  • Zemlickova H, Urbaskova P et al. Characteristics of Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and Staphylococcus aureus isolated from the nasopharynx of healthy children attending day-care centres in the Czech Republic. Epidemiol. Infect. 134, 1179–1187 (2006).
  • van Gils EJ, Hak E et al. Effect of seven-valent pneumococcal conjugate vaccine on Staphylococcus aureus colonisation in a randomised controlled trial. PLoS One 6(6), e20229 (2011).
  • van Gils EJ, Veenhoven RH, Rodenburg GD, Hak E, Sanders EA. Effect of 7-valent pneumococcal conjugate vaccine on nasopharyngeal carriage with Haemophilus influenzae and Moraxella catarrhalis in a randomized controlled trial. Vaccine 29(44), 7595–7598 (2011).
  • Dunne EM, Manning J, Russell FM, Robins-Browne RM, Mulholland EK, Satzke C. Effect of pneumococcal vaccination on nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Staphylococcus aureus in Fijian children. J. Clin. Microbiol. 50(3), 1034–1038 (2011).
  • Block SL, Hedrick J, Harrison CJ et al. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr. Infect. Dis. J. 23(9), 829–833 (2004).
  • Wiertsema SP, Kirkham L-AS, Corscadden KJ et al. Predominance of nontypeable Haemophilus influenzae in children with otitis media following introduction of a 3 + 0 pneumococcal conjugate vaccine schedule. Vaccine 29(32), 5163–5170 (2011).
  • Prymula R, Schuerman L. 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix. Expert Rev. Vaccines 8(11), 1479–1500 (2009).
  • Gerber JS, Coffin SE, Smathers SA, Zaoutis TE. Trends in the incidence of methicillin-resistant Staphylococcus aureus infection in children’s hospitals in the United States. Clin. Infect. Dis. 49, 65–71 (2009).
  • Ray GT, Suaya JA, Baxter R. Trends and characteristics of culture-confirmed Staphylococcus aureus infections in a large U.S. integrated health care organization. J. Clin. Microbiol. 50(6), 1950–1957 (2012).
  • Louie M, Louie L, Papia G, Talbot J, Lovgren M, Simor AE. Molecular analysis of the genetic variation among penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae serotypes in Canada. J. Infect. Dis. 179(4), 892–900 (1999).
  • Lovgren M, Spika JS, Talbot JA. Invasive Streptococcus pneumoniae infections: serotype distribution and antimicrobial resistance in Canada, 1992–1995. Can. Med. Assoc. J. 158(327), 331 (1998).
  • Davidson RJ, Low DE, Canadian Bacterial Surveillance Network. A cross-Canada surveillance of antimicrobial resistance in respiratory tract pathogens. Can. J. Infect. Dis. 158, 327–331 (1999).
  • Scheifele D, Halperin S, Pelletier L et al. Reduced susceptibility to penicillin among pneumococci causing invasive infection in children – Canada, 1991 to 1998. Can. J. Infect. Dis. 12(4), 241–246 (2001).
  • Zhanel GG, Palatnick L, Nichol KA. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian respiratory organism susceptibility study, 1997 to 2002. Antimicrob. Agents Chemother. 47(6), 1867–1874 (2003).
  • Karlowsky JA, Lagace-Wiens PR, Low DE, Zhanel GG. Annual macrolide prescription rates and the emergence of macrolide resistance among Streptococcus pneumoniae in Canada from 1995 to 2005. Int. J. Antimicrob. Agents 34, 375–379 (2009).
  • Vanderkooi OG, Low DE, Green K, Powis JE, McGeer A Predicting antimicrobial resistance in invasive pneumococcal infections. Clin. Infect. Dis. 40, 1288–1297 (2005).
  • Powis J, McGeer A, Green K et al. In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002. Antimicrob. Agents Chemother. 48, 3305–3311 (2004).
  • Pletz M, Shergill AP, McGee L, Whitney CG et al. Prevalence of first-step mutants among levofloxacin-susceptible invasive isolates of Streptococcus pneumoniae in the United States. Antimicrob. Agents Chemother. 50, 1561–1563 (2006).
  • Rozen DE, McGee L, Levin BR, Klugman KP. Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51(2), 412–416 (2007).
  • Adam HJ, Schurek KN, Nichol KA et al. Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005. Antimicrob. Agents Chemother. 51, 198–207 (2007).
  • Zhanel GG, Wang X, Nichol K et al. Molecular characterisation of Canadian paediatric multidrug-resistant Streptococcus pneumoniae from 1998–2004. Int. J. Antimicrob. Agents 28, 465–471 (2006).
  • Farrell DJ, Mendes RE, Ross JE, Sader HS, Jones RN. LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States. Antimicrob. Agents Chemother. 55(8), 3684–3690 (2011).
  • Billal DS, Feng J, Leprohon P, Légaré D, Ouellette M. Whole genome analysis of linezolid resistance in Streptococcus pneumoniae reveals resistance and compensatory mutations. BMC. Genomics. 12, 512–521 (2011).
  • Mera R, Miller LA, Fritsche TR, Jones RN. Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine. Microb. Drug Resist. 14, 101–107 (2008).
  • Proulx JF, Dery S, Jette LP et al. Pneumonia epidemic caused by a virulent strain of Streptococcus pneumoniae serotype 1 in Nunavik, Quebec. Can. Commun. Dis. Rep. 28(16), 129–131 (2002).
  • Herva E. Features of epidemiology of Streptococccus pneumoniae (serotype 1) in the Arctic. Int. J. Circumpolar Health 65(5), 379–381 (2006).
  • Ndiaye AA, De Wals P, Proulx JF, Ouakki M, Jetté L, Déry S. Impact of a mass immunization campaign to control an outbreak of severe respiratory infections in Nunavik, northern Canada. Int. J. Circumpolar Health 65(4), 297–304 (2006).
  • Mehiri-Zghal E, Decousser JW, Mahjoubi W et al. Molecular epidemiology of a Streptococcus pneumoniae serotype 1 outbreak in a Tunisian jail. Diagn. Microbiol. Infect. Dis. 66(2), 225–227 (2010).
  • Gratten M, Torzillo P, Morey F, Dixon J, Erlich J, Hagger J, Henrichden J. Distribution of capsular types and antibiotic susceptibility of invasive Streptococcus pneumoniae isolated from aborigines in Central Australia. J. Clin. Microbiol. 34, 338–341 (1996).
  • Dagan R, Gradstein S, Belmaker I et al. An outbreak Streptococcus pneumoniae serotype 1 in a closed community in southern Israel. Clin. Infect. Dis. 30, 319–321 (2000).
  • Tyrrell GJ, Lovgren M, Ibrahim Q et al. Epidemic of invasive pneumococcal disease, western Canada. Emerg. Infect. Dis. 18(5), 733–740 (2012).
  • Vanderkooi OG, Church DL, MacDonald J et al. Community-based outbreaks in vulnerable populations of invasive infections caused by Streptococcus pneumoniae serotypes 5 and 8 in Calgary, Canada. PLOS One 6(12), e28547 (2011).
  • Antonio M, Hakeem I, Awine T et al. Seasonality and outbreak of a predominant Streptococcus pneumoniae serotype 1 clone from the Gambia: expansion of ST217 hypervirulent clonal complex in West Africa. BMC. Microbiol. 8, 198 (2008).
  • Mercat A, Nguyen J, Dautzenberg B. An outbreak of pneumococcal pneumonia in two men’s shelters. Chest 99(1), 147–151 (1991).
  • Hennink M, Abbas Z, McDonald RR et al. Streptococcus pneumoniae outbreak in a rural Regina community. Can. Commun. Dis. Rep. 32(16), 181–186 (2006).
  • Norcross EW, Tullos NA et al. Assessment of Streptococcus pneumoniae capsule in conjunctivitis and keratitis in vivo neuraminidase activity increases in nonencapsulated pneumococci following conjunctival infection. Curr. Eyes Res. 35(9), 787–798 (2010).
  • Routledge M. Invasive pneumococcal disease (IPD) Winnipeg inner city immunization campaign. Public Health Bulletin by Winnipeg Regional Health Authority, 31 January 2011.
  • Hoge CW, Reichler MR, Dominguez EA et al. An epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail. N. Engl. J. Med. 331, 643–648 (1994).
  • Cherian T, Steinhoff MC, Harrison LH, Rohn D, McDougal LK, Dick J. A cluster of invasive pneumococcal disease in young children in child care. JAMA 271, 695–697 (1994).
  • CDC. Outbreak of invasive pneumococcal disease – Alaska, 2003–2004. MMWR Morb. Mortal. Wkly. Rep. 54, 72–75 (2005).
  • Zulz T, Wenger JD, Rudolph K et al. Streptococcus pneumoniae serotype 12F in Alaska: insights from molecular characterization of isolates associated with rural community outbreaks. J. Clin. Microbiol. 51(5), 1402–1407 (2013).
  • Deceuninck G, De Wals P, Boulianne N, De Serres G. Effectiveness of pneumococcal conjugate vaccine using a 2+1 infant schedule in Quebec, Canada. Pediatr. Infect. Dis. J. 29(6), 546–549 (2010).
  • Lee EH, Hosea S, Schulman E et al. Streptococcus pneumoniae serotype 12F outbreak in a homeless population – California, 2004; 54th Annual Epidemic Intelligence Service (EIS) Conference, 79, Abstract (2005).
  • Pilishvili T, Lexau C, Farley MM et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J. Infect. Dis. 201(1), 32–41 (2010).
  • Lepoutre A, Varon E, Georges S, Gutmann L, Levy-Bruhl D. Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001–2006. Euro Surveill. 13(35), 18962 (2008).
  • Linden VDM, Weiß S, Falkenhorst G et al. Four years of universal pneumococcal conjugate infant vaccination in Germany: impact on incidence of invasive pneumococcal disease and serotype distribution in children. Vaccine 30(40), 5880–5885 (2012).
  • Vestrheim DF, Lovoll O, Aaberge IS et al. Effectiveness of a 2 + 1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 26, 3277–3281 (2008).
  • Kaplan SL, Barson WJ, Lin PL et al. Serotype 19A is the most common serotype causing invasive pneumococcal infections in children. Pediatrics 125(3), 429–436 (2010).
  • Ongkasuwan J, Valdez TA, Hulten KG, Mason EO Jr, Kaplan SL. Pneumococcal mastoiditis in children and the emergence of multidrug-resistant serotype 19A isolates. Pediatrics 122(1), 34–39 (2008).
  • Xu Q, Pichichero ME, Casey JR, Zeng M. Novel type of Streptococcus pneumoniae causing multidrug-resistant acute otitis media in children. Emerg. Infect. Dis. 15(4), 547–551 (2009).
  • Moore MR, Gertz RE, Woodbury RL et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J. Infect. Dis. 197, 1016–1027 (2008).
  • Deng XD, Mackenzie R, Arya G, Pillai DR et al. Surveillance study of Streptococcus pneumoniae clinical isolates among Ontario children in Canada (2007–2011): epidemiology, serotyping, genotyping and antibiotic resistance patterns. Presented at: 52nd ICAAC. San Francisco, CA, USA, 9–12 September 2012 (G3-1562).
  • Pelton SI, Huot HMA, Finkelstein JA et al. Emergence of 19A as virulent and multidrug resistant pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 26, 468–472 (2007).
  • Reinerta RR, Jacobsb MR, Kaplanc SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine 28, 4249–4259 (2010).
  • Dagan R, Givon-Lavi N, Leibovitz E, Greenberg D, Porat N. Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J. Infect. Dis. 199(6), 776–785 (2009).
  • Choi EH, Kim SH et al. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg. Infect. Dis. 14(2), 275–281 (2008).
  • Pillai DR, Shahinas D, Buzina A et al. Genome-wide dissection of globally emergent multi-drug resistant serotype 19A Streptococcus pneumoniae. BMC Genomics 10, 642 (2009).
  • Dagan R, Eskola J, Leclerc C, Leroy O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect. Immun. 66(5), 2093–2098 (1998).
  • Wizemann TM, Heinrichs JH, Adamou JE et al. Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect. Immun. 69(3), 1593–1598 (2001).
  • Adamou JE, Heinrichs JH, Erwin AL et al. Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis. Infect. Immun. 69(2), 949–958 (2001).
  • Knaust A, Frosch M. Genome-based vaccines. Int. J. Med. Microbiol. 294(5), 295–301 (2004).
  • Moffitt KL, Malley R. Next generation pneumococcal vaccines. Curr. Opin. Immunol. 23(3), 407–413 (2011).
  • Denoël P, Philipp MT, Doyle L, Martin D, Carletti G, Poolman JT. A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae. Vaccine 29(33), 5495–5501 (2011).
  • Ota M, Greenwood B, Alderson M et al. Design of a streptococcus pneumoniae immunization and carriage (SPICAR) study to assess a novel pneumococcal protein-based vaccine in Gambian children. Presented at: The 8th ISPPD conference. Iguasu Falls, Brazil, 11–15 March 2012 (Poster 281).
  • Scott A. Protein based pneumococcal vaccines: why and which protein-based pneumococcal vaccines. Presented at: Proceedings of the Tenth Global Vaccine Research Forum. Geneva, Switzerland, 26–29 June 2011.
  • Bose RJC, Krishnakumar D, Jaganathan KS. The next generation pneumococcal vaccine: intranasal immunization with trimethyl chitosan encapsulated-PSAA induces mucosal as well as systemic immunity. Presented at: The 8th ISPPD conference. Iguasu Falls, Brazil, 11–15 March 2012 (Poster 255).
  • Kong I, Sato A, Yuki Y et al. Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by pneumococcus. Infect. Immun. 81(5), 1625–1634 (2013).
  • Webster J, Theodoratou E, Nair H, Seong AC et al. An evaluation of emerging vaccines for childhood pneumococcal pneumonia. BMC. Public Health. 11(Suppl. 3), 26 (2011).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.